CAMBRIDGE, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ: SURF), a clinical-stage ...
Data Provide Early Evidence of Anticancer Activity in Advanced Sarcoma and Inform Recommended Phase ...
Closes $35 million financing to advance Phase 2 and Phase 3 programs with drug ...
